4-氯苯基硫代乙酰胺 | 17518-48-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯苯基硫代乙酰胺
• 中文别名: 2-(4-氯苯基)硫代乙酰胺
• 英文名称: 4-chlorophenylthioacetamide
• 英文别名: 2-(4-chlorophenyl)ethanethioamide
• CAS: 17518-48-8
• 化学式: C₈H₈ClNS
• 分子量: 185.677
• InChiKey: QHCDYIRWTPEABF-UHFFFAOYSA-N

物化性质

• 熔点：
  129-131 °C
• 稳定性/保质期：

  常温常压下稳定，应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2930909090
• 储存条件：
  常温密闭避光，存于通风干燥处。

SDS

Name:	4-Chlorophenylthioacetamide 98% Material Safety Data Sheet
Synonym:	4-Chlorophenylethanethioamide
CAS:	17518-48-8

Section 1 - Chemical Product MSDS Name:4-Chlorophenylthioacetamide 98% Material Safety Data Sheet
Synonym:4-Chlorophenylethanethioamide

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17518-48-8	4-Chlorophenylthioacetamide	98%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17518-48-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 129 - 130 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8ClNS
Molecular Weight: 185.68

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17518-48-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chlorophenylthioacetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 17518-48-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17518-48-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17518-48-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-氯苯基硫代乙酰胺

4-氯苯基硫代乙酰胺是一种有机中间体，可通过对氯苄腈为原料制备得到。文献报道其可用于制备AT2受体激动剂。

制备方法

将10 mmol的P4S10溶解于5 mL EtOH中并搅拌1小时。随后加入5 mmol的对氯苄腈，并将混合物加热至回流2-6.5小时。冷却后，用200 mL CHCl3洗涤混合物，有机相经CaCl2干燥，最后在真空条件下浓缩。残留物通过色谱分离（乙酸乙酯-正己烷，40∶60）得到纯的4-氯苯基硫代乙酰胺，产率为47-95%，收率可达90%。

反应信息

• 作为反应物：
  描述：

  4-氯苯基硫代乙酰胺 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 30.0h， 生成 1,3-bis-{4-[2-(4-chloro-benzyl)-thiazol-4-yl]-phenyl}-thiourea
  参考文献：
  名称：

  结核的化学治疗，第九部分：新的噻唑基硫代氨基甲酸酯类化合物的合成和筛选

  摘要：

  将近八十个取代的硫代氨基甲酸酯，即p-（2-噻唑基）-，p-（4-噻唑基）-和p-（5-噻唑基）-p-烷氧基-硫代氨基甲酸酯，以及p-p′-双（4-已经合成并研究了噻唑基）-硫代氨基甲酰苯胺，以及一些在含有p'-烷氧基的苯环上具有卤素的噻唑基硫代氨基甲酰苯胺，并进行了体外抗结核活性的研究。还描述了作为中间体制备的40多种新的取代噻唑。对-（4-噻唑基）-p'-烷氧基-硫代氨基甲酸酯类在本研究中通常显示出最大的体外抑结核活性。p-（2,5-二甲基-4-噻唑基）-p'-n-丙氧基硫代氨基甲酰苯胺具有与异烟酸酰肼（INH）相同的体外抑结核活性（0.04 mcg./ml。），但在25℃时未产生抑菌血清浓度与INH相同的口服剂量水平。

  DOI：

  10.1002/jps.2600580713
• 作为产物：
  描述：

  对氯苯乙腈 在 diphosphorus pentasulfide 、 乙醇 作用下， 反应 2.0h， 以90%的产率得到4-氯苯基硫代乙酰胺
  参考文献：
  名称：

  五硫化磷：一种用于从腈制备硫代酰胺的温和多功能试剂

  摘要：

  开发了一种简单、高效、新的方法，用于从腈中合成硫代酰胺。多种芳香族和脂肪族腈在五硫化二磷存在下的反应以高产率提供相应的硫代酰胺。该方法简便、快速、收率高，可用于从腈中合成硫代酰胺。

  DOI：

  10.1055/s-2005-918507

文献信息

• Synthesis and Antimicrobial Activities of Novel Series of 3-(4-(2-substituted thiazol-4-yl)phenyl)-2-(4-methyl-2-substituted thiazol-5-yl)thiazolidin-4-one Derivatives
  作者：Shivaji H. Shelke、Pravin C. Mhaske、Sachin Narkhade、Vivek D. Bobade

  DOI：10.1002/jhet.1789

  日期：2014.7

  In the present investigation, a novel series of 3‐(4‐(2‐substituted thiazol‐4‐yl)phenyl)‐2‐(4‐methyl‐2‐substituted thiazol‐5‐yl)thiazolidin‐4‐one derivatives were synthesized by condensation of 2‐substituted‐4‐methylthiazole‐5‐carbaldehyde with 4‐(2‐substituted thiazol‐4‐yl)benzenamine followed by cyclo‐condensation with thioglycolic acid in toluene. All the newly synthesized compounds were characterized

  在本研究中，一系列新的3-（4-（2-取代噻唑-4-基）苯基）-2-（4-甲基-2-取代噻唑-5基）噻唑烷-4-酮衍生物是合成方法是将2-取代4-甲基噻唑5-甲醛与4-（2-取代噻唑4-基）苯甲胺缩合，然后与巯基乙酸在甲苯中进行环缩合。所有新合成的化合物均通过光谱（IR，1 H NMR，13 C NMR和Mass）方法进行了表征。筛选标题化合物的定量抗菌活性（最小抑制浓度）。所有化合物7a，7b，7c，7d，7e，7f，7g，7h和8a，8b，8c，8d，8e，8f，8g，8h显示中度至良好的抗菌活性，而化合物（7a，7b，7c，7d，7e，7f，7g，7h）也显示中度抗真菌活性。
• Synthesis and Biological Screening of Thiazole-5-Carboxamide Derivatives
  作者：Pravin C. Mhaske、Kamlesh S. Vadgaonkar、Rahul P. Jadhav、Vivek D. Bobade

  DOI：10.5012/jkcs.2011.55.5.882

  日期：2011.10.20

  by fluorine as in N(4-(2-(3,4-dichlorobenzylthiazol-4-yl)phenyl)-2-(4-fluorobenzyl)-4-methylthiazole-5-carboxamide (5i), it showed antibacterial activity. N-(4-(2-(4-fluorobenzylthiazol-4-yl)phenyl)-2-(4-chlorobenzyl)-4-methylthiazole-5-carboxamide (5m) showed antifungal activity, but when one chlorine atom is added at 2-position as in N-(4-(2-(4-fluorobenzyl)thiazol-4-yl)phenyl)-2-(2,4-dichloroben

  噻唑衍生物因其易于获得，化学活性多样而得到了广泛的研究。噻唑的化学作用继续引起合成有机化学家的注意，因为它们具有多种多样的生物活性，例如抗菌，抗结核，抗癌，抗真菌和消炎活性，具有1-5的活性。6-9还报道了4-（4-氨基苯基）-噻唑具有抗结核活性。10个5-唑羧酰胺衍生物显示出抗缺氧活性。11芳基咪唑基羧酰胺衍生物被证明是大麻素CB1受体拮抗剂。12,13基于这些观察结果，合成了取代的噻唑羧酰胺并进行了微生物筛选。在此处，我们报告了在DMF中使用EDC-HOBt偶联合成N-（4-（2-（苄基噻唑-4-基）苯基）-2-苄基-4-甲基噻唑-5-羧酰胺衍生物的简单有效的方法抗菌活性。通过使2-苄基-4-甲基噻唑-5-羧酸3a-c与2-甲基/取代的苄基-4-（4-氨基苯基）噻唑2a-f在EDC-存在下反应来合成目标化合物5a-n。 DMF中的HOBt收率很高（方案1）。表1列出了羧酰胺衍生物5a-
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004099178A1

  公开（公告）日：2004-11-18

  Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

  公式（I）的化合物：包含它们的组合物，制备它们的方法以及它们在医学疗法中的用途（例如在温血动物中调节CCR5受体活性）。
• Serotonin antagonists
  申请人：Burroughs Wellcome Co.

  公开号：US03987158A1

  公开（公告）日：1976-10-19

  A compound of the formula ##EQU1## or an acid addition salt thereof wherein R.sup.1 and R.sup.2 are the same or different and each is a phenyl or thien-2-yl group optionally substituted in one or more positions by a substituent selected from the class consisting of halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, phenyl, phenoxy, phenyl-(lower-alkyl) and phenyl-(lower-alkoxy), each of the said phenyl, phenoxy, phenyl-(lower-alkyl) and phenyl-(lower-alkoxy) substituent groups being optionally substituted in one or more positions by a member selected from the class consisting of halogen, lower alkyl, lower alkoxy, hydroxy, and lower alkylthio; A.sup.1 is a divalent straight or branched alkylene group containing from two to six carbon atoms and one or two divalent atoms which are each an oxygen or sulphur atom, provided that there are at least two carbon atoms between the divalent atom and the --NH-- group and between the two divalent atoms; and A.sup.2 is the methylene group --CH.sub.2 --.

  式##EQU1##的化合物或其酸加合盐，其中R.sup.1和R.sup.2相同或不同，每个都是苯基或噻吩-2-基团，可以在一个或多个位置被来自卤素、低烷基、低烷氧基、羟基、低烷硫基、苯基、苯氧基、苯基-(低烷基)和苯基-(低烷氧基)的取代基中选择的取代基取代，所述的苯基、苯氧基、苯基-(低烷基)和苯基-(低烷氧基)取代基中的每一个可以在一个或多个位置被来自卤素、低烷基、低烷氧基、羟基和低烷硫基的取代基中选择的成员取代；A.sup.1是含有两至六个碳原子和一个或两个二价原子的直链或支链烷基基团，每个二价原子都是氧原子或硫原子，前提是二价原子和--NH--基团之间以及两个二价原子之间至少有两个碳原子；A.sup.2是亚甲基基团--CH.sub.2 --。
• THIAZOLE DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2530078A1

  公开（公告）日：2012-12-05

  Provided is a compound having an agonist action on GPR52, which is useful as a prophylactic or therapeutic drug for mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种对GPR52具有激动剂作用的化合物，该化合物可作为预防或治疗精神疾病如精神分裂症等的药物。一种由以下通式（I）表示的化合物：其中各个符号的定义如说明书中所述，或其盐形式。